DIFICID(Fidaxomicin) Instructions:Uses,Dosage, Side Effects

DIFICID® (fidaxomicin) is a macrolide antibacterial indicated for treating Clostridioides difficile-associated diarrhea (CDAD) in adults and pediatric patients ≥6 months old. It acts locally in the gastrointestinal tract by inhibiting bacterial RNA synthesis via binding to RNA polymerases, exhibiting bactericidal activity against C. difficile.

Administered orally as tablets (200 mg) or suspension (40 mg/mL), the standard regimen is twice daily for 10 days. Clinical trials demonstrate non-inferiority to vancomycin for initial cure, with superior sustained response rates 25 days post-treatment. Common adverse reactions include nausea, vomiting, abdominal pain, and anemia in adults. Minimal systemic absorption limits its use to CDAD only.